Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 296 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mouth Rinse Clear all
Completed Phase 3 Interventional Results available

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00293462
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions
sargramostim, oral salt and soda mouthwash
Biological · Other
Lead sponsor
Marilyn Dodd
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth

NCT01122862
View directory record Official record
Conditions
Healthy Subjects
Interventions
0.12% chlorhexidine mouthrinse, Cosmetic mouthrinse, Sterile water
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 18, 2026, 2:26 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Determination of the Safety and Efficacy of a Novel Oral Rinse on Oral Health

NCT04197427
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
Experimental Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 18, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Comparing Mouth Rinses (and Chewing Gum) in Regard to Streptococcus Mutans Reduction

NCT02598778
View directory record Official record
Conditions
Dental Caries
Interventions
Chlorhexidine gluconate (0.12%), Sodium Fluoride (0.05%), Paraffin wax chewing gum (sugar-free), Deionized water
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection

NCT04931004
View directory record Official record
Conditions
Covid19
Interventions
Mouthwash Product
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Two-Week Study of an Anticavity Low pH Mouthwash

NCT06010758
View directory record Official record
Conditions
Healthy
Interventions
Listerine Experimental Mouthwash, Colgate Cavity Protection Toothpaste, Listerine Total Care Zero, Listerine Cool Mint Zero
Drug · Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash

NCT01566448
View directory record Official record
Conditions
Mucositis
Interventions
Ketamine
Drug
Lead sponsor
Aaron Cumpston, PharmD, BCOP
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ibuprofen Inhibits Human Sweet Taste

NCT06291337
View directory record Official record
Conditions
Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants, Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy Participants
Interventions
Inhibition of Sweet Taste by Ibuprofen Oral Rinses, Inhibition of Sweet Taste by Naproxen Oral Rinses
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 18, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional Results available

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

NCT02062632
View directory record Official record
Conditions
Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma, Mesothelioma, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Pleura, Metastatic Malignant Neoplasm in the Spinal Cord, Non-Small Cell Lung Carcinoma, Sarcoma, Small Cell Lung Carcinoma, Thymic Carcinoma, Thymoma, Thyroid Gland Carcinoma
Interventions
Doxepin Hydrochloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Interproximal Cleaning Modalities on Oral Health

NCT02187016
View directory record Official record
Conditions
Gingivitis
Interventions
AirFloss + BreathRx, AirFloss + Listerine, Dental Floss, Manual Toothbrush
Device
Lead sponsor
Philips Oral Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 18, 2026, 2:26 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912
View directory record Official record
Conditions
Lung Neoplasm Malignant
Interventions
Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
9
States / cities
Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque

NCT04921371
View directory record Official record
Conditions
Gingivitis, Plaque
Interventions
Colgate® Cavity Protection Toothpaste, Listerine® Cool Mint®, Concept Curve Winter Series Toothbrush, 5% Hydroalcohol Mouthrinse, Mouthrinse Prototype 1, Mouthrinse Prototype 2
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Oral Rinse for Xerostomia

NCT04289051
View directory record Official record
Conditions
Xerostomia
Interventions
HYDRAL Oral Rinse, BIOTENE® Oral Rinse, Placebo Oral Rinse
Device
Lead sponsor
Sunstar Americas
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determination of the Oral Irritation Potential of a Fluoride Rinse in Children

NCT06798441
View directory record Official record
Conditions
Healthy
Interventions
Brush Only, Brush / Rinse (Jolly Rancher Prototype), Brush / Rinse (LISTERINE® Total Care Zero Alcohol)
Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
6 Years to 11 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Not applicable Interventional Results available

Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance

NCT01209234
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus
Interventions
Standard-of-Care Education, MRSA Decolonization
Behavioral · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
2,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
24
States / cities
Aliso Viejo, California • Anaheim, California • Downey, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Not applicable Interventional

A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients

NCT03886623
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Methicillin-Sensitive Staphylococcus Aureus Infection
Interventions
4-day systematic oral hygiene, Standard of Care oral care
Procedure · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Effects of Nystatin Suspension Oral Application on Oral Microbial Community

NCT04550546
View directory record Official record
Conditions
Dental Caries
Interventions
Nystatin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 18, 2026, 2:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry

NCT05196061
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Questionnaire, Stool sample, Skin swab, Oral rinse
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Treatment and/or Prevention of Urinary Tract Infections

NCT00801021
View directory record Official record
Conditions
Cystitis, Urinary Tract Infections
Interventions
Frio Mouth Rinse
Drug
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

NCT02480114
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions
Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 18, 2026, 2:26 AM EDT
Recruiting Phase 3 Interventional

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
39
States / cities
Mobile, Alabama • Chandler, Arizona • Duarte, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 18, 2026, 2:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340
View directory record Official record
Conditions
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
55
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 18, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

NCT02229539
View directory record Official record
Conditions
Acute Oral Mucositis Pain
Interventions
doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
350
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 221 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 18, 2026, 2:26 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
51
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 18, 2026, 2:26 AM EDT